In 1993, it was reported that treatment with anti‐VEGF monoclonal antibodies resulted in a significant reduction in vessel density and a significant delay in tumor growth in nude mice carrying rhabdomyosarcoma, glioblastoma multiforme (GBM), and leiomyosarcoma xenografts.266. The gene discussed is VEGFA; the disease is neoplasm.